Biotech Archives - Page 723 of 795

3 minute read

Amgen Announces Topline Data From Lumakras Phase 3 Trial In Non-small Cell Lung Cancer Met Its Primary Endpoint

August 30, 4:05 PM

LUMAKRAS Met Primary Endpoint of Progression-Free Survival, Demonstrating Superiority Over Standard of Care Docetaxel Chemotherapy, in KRAS G12C-Mutated Non-Small Cell Lung Cancer Detailed Data to be Presented

AMGN

2 minute read

Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes Of The ClotTriever System In Deep Vein Thrombosis

By Benzinga Newsdesk

August 30, 4:02 PM

IRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) ("Inari") a medical device company with a mission to treat and transform the lives of patients suffering from venous and otherIRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc.

NARI

1 minute read

This Women Health Stock Gets Analyst Downgrade On ‘Approvability Issues, Restructuring’

By Vandana Singh

August 30, 2:56 PM

HC Wainwright has downgraded ObsEva SA (NASDAQ:OBSV) from a Buy to Neutral without a price target. Late last month, the FDA notified…

OBSV

1 minute read

Y-mAbs Gets Regulatory Approval In Israel For Neuroblastoma Candidate

By Ragothaman Srinivasan

August 30, 1:08 PM

The Israeli Ministry of Health has approved Y-mAbs Therapeutics’ (NASDAQ: YMAB) lead drug DANYELZA in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

TAK

1 minute read

With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report

By Vandana Singh

August 30, 12:28 PM

Last week, Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) dengue vaccine, Qdenga, was approved in Indonesia for individuals six to 45 years of age.…

GSK

1 minute read

Neurocrine Biosciences Buys UK-Based Hormone Therapy Player

By Vandana Singh

August 30, 12:23 PM

Neurocrine Biosciences Inc (NASDAQ:NBIX) has agreed to pay £48.3 million for the U.K. hormone therapy group, Diurnal Group Plc. The 27.5p share…

NBIX

1 minute read

AstraZeneca Scores Its First Global Approval For Antibody Evusheld As COVID-19 Treatment

By Vandana Singh

August 30, 12:21 PM

The regulatory authority in Japan has approved AstraZeneca plc’s (NASDAQ:AZN) Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination for…

AZN

1 minute read

Jaguar Health Seeks FDA Nod For Cholera Candidate Study

By Ragothaman Srinivasan

August 30, 10:48 AM

Jaguar Health (NASDAQ: JAGX) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its subsidiary Napo's NP-300 drug product candidate for the symptomatic relief of diarrhea from cholera.

JAGX

1 minute read

Outlook Therapeutics Shares Pop After Filing US Application For Its Lead Eye Disease Candidate

By Vandana Singh

August 30, 9:39 AM

Outlook Therapeutics Inc (NASDAQ:OTLK) has re-submitted its marketing application to the FDA, seeking approval for ONS-5010 for wet age-related macular degeneration…

OTLK

1 minute read

Connect Biopharma’s Candidate For Skin Disease-Associated Itch Shows Encouraging Safety Profile

By Vandana Singh

August 30, 9:36 AM

Connect Biopharma Holdings Limited (NASDAQ:CNTB) has completed its first-in-human Phase 1 study of CBP-174 in healthy adults. CBP-174, a highly selective,…

CNTB